بدائل البحث:
teer decrease » greater decrease (توسيع البحث)
nn decrease » _ decrease (توسيع البحث), gy decreased (توسيع البحث), b1 decreased (توسيع البحث)
a decrease » _ decrease (توسيع البحث), _ decreased (توسيع البحث), _ decreases (توسيع البحث)
09 a » 19 a (توسيع البحث), 09 1 (توسيع البحث), 09 0 (توسيع البحث)
teer decrease » greater decrease (توسيع البحث)
nn decrease » _ decrease (توسيع البحث), gy decreased (توسيع البحث), b1 decreased (توسيع البحث)
a decrease » _ decrease (توسيع البحث), _ decreased (توسيع البحث), _ decreases (توسيع البحث)
09 a » 19 a (توسيع البحث), 09 1 (توسيع البحث), 09 0 (توسيع البحث)
-
61
-
62
-
63
Decreased clonogenic capacity of U87MG and U251MG glioma cells dependent on SHG-44 concentration.
منشور في 2025"…<b>(B)</b> A significant decrease in the proliferative clonal capacity of U251MG colonies was observed with 50ΜM and 100ΜM SHG-44 treatment. …"
-
64
DataSheet_1_Decrease in Serum Urate Level Is Associated With Loss of Visceral Fat in Male Gout Patients.docx
منشور في 2021"…</p>Results<p>ULT resulted in a mean (standard deviation) decrease in SU level (464.22 ± 110.21 μmol/L at baseline, 360.93 ± 91.66 μmol/L at the final visit, p <0.001) accompanied by a decrease in median (interquartile range) VFA [97.30 (81.15–118.55) at baseline, 90.90 (75.85–110.05) at the final visit, p < 0.001]. …"
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
Temporal profiles of the key BO-NN features.
منشور في 2020"…Right plot show the gradual decrease in the TM tuning for the features highlighted in <b>c</b> as well as the gradual increase in the temporal response profile (i.e. optimal shifts for the prediction of the key BO-NN features using Praat features shown in <b>a</b>). …"
-
75
-
76
-
77
Annual treatment frequencies in recurrence and non-recurrence groups.
منشور في 2025"…Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …"
-
78
Annual treatment frequencies in all eyes.
منشور في 2025"…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …"
-
79
Annual number of outpatient visits in recurrence and non-recurrence groups.
منشور في 2025"…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …"
-
80
Annual number of outpatient visits in all eyes.
منشور في 2025"…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …"